PACS

AI Memo

PACS Group

As of 2026-05-29/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Raised FY26 EBITDA guidance plus buyback support • 2026-05-11

Expected move: +26%

Biggest risk

The stock still carries meaningful overhangs: management says disclosure controls were not effective as of Mar. 31, 2026, material weaknesses remain unremediated, and DOJ/SEC investigations into billing, accounting, and disclosure matters are ongoing. Guidance also excludes future acquisitions, so upside still depends on organic execution and reimbursement conditions. [#10-Q-2026-05-11][#8-K-2026-05-11]

Invalidation

Break below $30 or thesis failure.

What would change my mind?

The bull case is that PACS is showing real operating leverage: Q1 revenue +11.2%, adjusted EBITDA +74.6%, occupancy up to 90.9%, and guidance moved higher to $605M-$625M adjusted EBITDA with a $250M buyback on top. Post-print analyst revisions were constructive, with Truist raising its target to $52 from $50 and lifting 2026 adjusted EBITDA estimates to $617M from $566M; Oppenheimer also raised its target to $48 from $42. [#8-K-2026-05-11]

Research note

Recommendation

—

Confidence

medium

As of

2026-05-29

Base target

$46

p=50%

Bull target

$52

p=30%

Bear target

$30

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Occupancy and maturity gains can sustain compounding
The bull case is that PACS is showing real operating leverage: Q1 revenue +11.2%, adjusted EBITDA +74.6%, occupancy up to 90.9%, and guidance moved higher to $605M-$625M adjusted EBITDA with a $250M buyback on top.
Post-print analyst revisions were constructive, with Truist raising its target to $52 from $50 and lifting 2026 adjusted EBITDA estimates to $617M from $566M; Oppenheimer also raised its target to $48 from $42.

BearKey bullets

Guidance excludes future acquisitions, so the updated outlook is more dependent on organic occupancy, mix, and pricing execution than on M&A.
[#8-K-2026-05-11]
Ongoing DOJ and SEC investigations into billing, accounting, and disclosure matters can add legal cost, restrict operating flexibility, and create downside if findings are adverse.

WatchKey bullets

Raised FY26 EBITDA guidance plus buyback support

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $46 (p=50%)

Bull/Bear spread: +41% / -19%

Vs latest close: Bull +41% · Base +26% · Bear -19%

Scenario probabilities

Bull Target: $52 (p=30%)Base Target: $46 (p=50%)Bear Target: $30 (p=20%)

Commentary

Sentiment is constructive but not clean: the Q1 print triggered a roughly 23.7% premarket jump, and later analyst follow-through was positive, but the market has already repriced much of the beat. Coverage remains thin, the peer set is loose, and the unresolved legal/control overhang keeps this in monitoring territory rather than a clean bullish reset.

As of 2026-05-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Occupancy and maturity gains can sustain compounding

Scenarios

Bull Target (Scenario probability)

$52 / p=30% prob

Base Target (Scenario probability)

$46 / p=50% prob

Bear Target (Scenario probability)

$30 / p=20% prob

Price $37 as of 2026-06-02

Nearest Scenario: Bear (∆ 19%)

Targets vs latest close: Bull +41% · Base +26% · Bear -19%

Sentiment & Exposure

News Sentiment (30d)

0.62

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-11
Raised FY26 EBITDA guidance plus buyback support
Management lifted full-year 2026 adjusted EBITDA guidance to $605M-$625M from $555M-$575M, reaffirmed revenue guidance of $5.65B-$5.75B, and authorized a $250M share repurchase program, creating a cleaner capital-return story. [#8-K-2026-05-11]
Prob 72.00% • Move 6.00% • Priced-in 55.00%
EVENT2026-05-12
Q1 beat already drove a sharp rerate
First-quarter 2026 revenue rose 11.2% to $1.42B, adjusted EBITDA rose 74.6% to $170.4M, and net income increased to $80.7M; the release also triggered a roughly 23.7% premarket jump to $37.97, so a lot of the immediate surprise has already been absorbed. [#8-K-2026-05-11]
Prob 78.00% • Move 3.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Occupancy and maturity gains can sustain compounding
2026-12-31
Same-store SNF revenue increased 8.0%, occupancy improved to 90.9%, 78.4% of the skilled-nursing portfolio earned 4- or 5-star CMS quality ratings, and liquidity stayed high at $795.1M with net leverage near 0.1x, supporting a longer-duration operating and valuation recovery thesis. [#8-K-2026-05-11]
Prob 60% • Move 9% • Priced-in 40%

Risks

Guidance excludes future acquisitions, so the updated outlook is more dependent on organic occupancy, mix, and pricing execution than on M&A. [#8-K-2026-05-11]
Ongoing DOJ and SEC investigations into billing, accounting, and disclosure matters can add legal cost, restrict operating flexibility, and create downside if findings are adverse. [#10-Q-2026-05-11]
Reimbursement, labor, quality-rating, and California program dependence remain structural risks for the post-acute model. [#8-K-2026-05-11]
Unremediated material weaknesses in internal control over financial reporting and disclosure controls remain a real risk; management says the controls were not effective as of Mar. 31, 2026 and remediation is still in progress. [#10-Q-2026-05-11]

Peers

Symbol	Summary
CHE	Closest same-sector comp in the packet; it is still only a loose peer, but it is more relevant than device names because it shares healthcare-services exposure and reimbursement sensitivity.
HIMS	A looser healthcare-services growth comp that can help frame valuation and sentiment, but its consumer telehealth model is not a clean operating match for PACS.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-29

AI Stock Memo: PACS - PACS Group - RankAlpha